Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
Revenue
Cyclopharm Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Revenue
AU$27.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Somnomed Ltd
ASX:SOM
|
Revenue
AU$100.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Cochlear Ltd
ASX:COH
|
Revenue
AU$2.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Revenue
AU$1.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
31%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Revenue
AU$58.2m
|
CAGR 3-Years
21%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Revenue
AU$8.6m
|
CAGR 3-Years
76%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
Cyclopharm Ltd
Glance View
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
See Also
What is Cyclopharm Ltd's Revenue?
Revenue
27.6m
AUD
Based on the financial report for Dec 31, 2024, Cyclopharm Ltd's Revenue amounts to 27.6m AUD.
What is Cyclopharm Ltd's Revenue growth rate?
Revenue CAGR 10Y
9%
Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Cyclopharm Ltd have been 16% over the past three years , 14% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet